Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 53 citing articles:

From nature to therapy: Luteolin's potential as an immune system modulator in inflammatory disorders
Md Sadique Hussain, Gaurav Gupta, Ahsas Goyal, et al.
Journal of Biochemical and Molecular Toxicology (2023) Vol. 37, Iss. 11
Closed Access | Times Cited: 56
Is depression the missing link between inflammatory mediators and cancer?
Barbara Polityńska, Olga Pokorska, Anna M. Wojtukiewicz, et al.
Pharmacology & Therapeutics (2022) Vol. 240, pp. 108293-108293
Closed Access | Times Cited: 44
Could psychedelic drugs have a role in the treatment of schizophrenia? Rationale and strategy for safe implementation
Gilly Wolf, Sandeep Singh, Karin Blakolmer, et al.
Molecular Psychiatry (2022) Vol. 28, Iss. 1, pp. 44-58
Closed Access | Times Cited: 39
Discovering the Potential Mechanisms of Medicinal Mushrooms Antidepressant Activity: A Review
Jan Lazur, Kamil Hnatyk, Katarzyna Kała, et al.
Antioxidants (2023) Vol. 12, Iss. 3, pp. 623-623
Open Access | Times Cited: 34
Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment
Jenessa N. Johnston, Bashkim Kadriu, Josh Allen, et al.
Neuropharmacology (2023) Vol. 226, pp. 109422-109422
Open Access | Times Cited: 33
Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
M. Ishrat Husain, Nicole Ledwos, Elise Fellows, et al.
Frontiers in Psychiatry (2023) Vol. 13
Open Access | Times Cited: 31
The Effect of Combined Treatment of Psilocybin and Eugenol on Lipopolysaccharide-Induced Brain Inflammation in Mice
Timur Zanikov, Marta Gerasymchuk, Esmaeel Ghasemi Gojani, et al.
Molecules (2023) Vol. 28, Iss. 6, pp. 2624-2624
Open Access | Times Cited: 28
Psychedelics for acquired brain injury: a review of molecular mechanisms and therapeutic potential
Josh Allen, Shannon Dames, Claire J. Foldi, et al.
Molecular Psychiatry (2024) Vol. 29, Iss. 3, pp. 671-685
Closed Access | Times Cited: 14
Psychedelic Therapy: A Primer for Primary Care Clinicians—Psilocybin
Burton J. Tabaac, Kenneth Shinozuka, Alejandro Arenas, et al.
American Journal of Therapeutics (2024) Vol. 31, Iss. 2, pp. e121-e132
Closed Access | Times Cited: 9
Neurobiological mechanisms of antidepressant properties of psilocybin: A systematic review of blood biomarkers
Juliana Lima Constantino, Jens H. van Dalfsen, Sara Massetti, et al.
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2025) Vol. 136, pp. 111251-111251
Open Access | Times Cited: 1
Exploring Psilocybe cubensis Strains: Cultivation Techniques, Psychoactive Compounds, Genetics and Research Gaps
Eyal Kurzbaum, Tomáš Páleníček, Amiel Shrchaton, et al.
Journal of Fungi (2025) Vol. 11, Iss. 2, pp. 99-99
Open Access | Times Cited: 1
Anti-inflammatory activity of d-pinitol possibly through inhibiting COX-2 enzyme: in vivo and in silico studies
Mst. Farjanamul Haque, Heba A. S. El‐Nashar, Md. Showkoth Akbor, et al.
Frontiers in Chemistry (2024) Vol. 12
Open Access | Times Cited: 8
Psilocybin for the treatment of Alzheimer’s disease
Siyi Zheng, Rong Ma, Yang Yang, et al.
Frontiers in Neuroscience (2024) Vol. 18
Open Access | Times Cited: 7
Deciphering psilocybin: Cytotoxicity, anti-inflammatory effects, and mechanistic insights
Salma Laabi, Claire LeMmon, Callie Vogel, et al.
International Immunopharmacology (2024) Vol. 130, pp. 111753-111753
Closed Access | Times Cited: 6
Therapeutic modulation of the kynurenine pathway in severe mental illness and comorbidities: A potential role for serotonergic psychedelics
Antonella Campanale, Antonio Inserra, Stefano Comai
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 134, pp. 111058-111058
Open Access | Times Cited: 6
Anti-Inflammatory Effects of Serotonin Receptor and Transient Receptor Potential Channel Ligands in Human Small Intestinal Epithelial Cells
Gregory Ian Robinson, Dongping Li, Bo Wang, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 8, pp. 6743-6774
Open Access | Times Cited: 14
Psilocybin for dementia prevention? The potential role of psilocybin to alter mechanisms associated with major depression and neurodegenerative diseases
Zarah R. Haniff, Mariia Bocharova, Tim Mantingh, et al.
Pharmacology & Therapeutics (2024) Vol. 258, pp. 108641-108641
Open Access | Times Cited: 5
Psilocybin Efficacy and Mechanisms of Action in Major Depressive Disorder: a Review
Damien Prouzeau, Ismaël Conejero, Peter L. Voyvodic, et al.
Current Psychiatry Reports (2022) Vol. 24, Iss. 10, pp. 573-581
Closed Access | Times Cited: 20
A Comprehensive Review of the Current Status of the Cellular Neurobiology of Psychedelics
Blerida Banushi, Vince Polito
Biology (2023) Vol. 12, Iss. 11, pp. 1380-1380
Open Access | Times Cited: 13
Psilocybin and Eugenol Reduce Inflammation in Human 3D EpiIntestinal Tissue
Gregory Ian Robinson, Dongping Li, Bo Wang, et al.
Life (2023) Vol. 13, Iss. 12, pp. 2345-2345
Open Access | Times Cited: 11
Psilocybin and eugenol prevent DSS-induced neuroinflammation in mice
Timur Zanikov, Marta Gerasymchuk, Gregory Ian Robinson, et al.
Biocatalysis and Agricultural Biotechnology (2024) Vol. 56, pp. 103033-103033
Closed Access | Times Cited: 4
Edible Mushrooms and Hypertension: A Focus on the Biochemical Outcome During Treatment
Olalekan Bukunmi Ogunro
Reference series in phytochemistry (2025), pp. 1-31
Closed Access
Edible Mushroom and Respiratory Diseases
Arinze Favour Anyiam, Onyinye Cecilia Arinze-Anyiam, Emmanuel Anyachukwu Irondi
Reference series in phytochemistry (2025), pp. 1-39
Closed Access
Discovery and Relevance of Novel Pharmacological Substances from Beneficial Mushrooms
Oluwabukola Atinuke Popoola, Charles Oluwaseun Adetunji, Oluwafemi Adebayo Oyewole, et al.
(2025), pp. 183-207
Closed Access
LPS-Induced Liver Inflammation Is Inhibited by Psilocybin and Eugenol in Mice
Gregory Ian Robinson, Marta Gerasymchuk, Timur Zanikov, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 451-451
Open Access
Page 1 - Next Page

Scroll to top